United States Renal Data System. Morbidity and mortality in patients with CKD. In: 2024 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2025.

Wang TZ, Kodiyanplakkal RPL, Calfee DP. Antimicrobial resistance in nephrology. Nat Rev Nephrol. 2019;15(8):463–81.

Article  PubMed  PubMed Central  Google Scholar 

Barbhaiya RH, Knupp CA, Forgue ST, et al. Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther. 1990;48(3):268–76.

Article  CAS  PubMed  Google Scholar 

Leroy A, Fillastre JP, Etienne I, et al. Pharmacokinetics of meropenem in subjects with renal insufficiency. Eur J Clin Pharmacol. 1992;42(5):535–8.

Article  CAS  PubMed  Google Scholar 

Chimata M, Nagase M, Suzuki Y, et al. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrob Agents Chemother. 1993;37(2):229–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leroy A, Leguy F, Borsa F, et al. Pharmacokinetics of ceftazidime in normal and uremic subjects. Antimicrob Agents Chemother. 1984;25(5):638–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Merdjan H, Tarral A, Das S, et al. Phase 1 study assessing the pharmacokinetic profile and safety of avibactam in patients with renal impairment. J Clin Pharmacol. 2017;57(2):211–8.

Article  CAS  PubMed  Google Scholar 

Huwyler T, Lenggenhager L, Abbas M, et al. Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study. Clin Microbiol Infect. 2017;23(7):454–9.

Article  CAS  PubMed  Google Scholar 

Lamoth F, Buclin T, Pascual A, et al. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother. 2010;54(10):4360–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Imani S, Buscher H, Marriott D, et al. Too much of a good thing: a retrospective study of beta-lactam concentration-toxicity relationships. J Antimicrob Chemother. 2017;72(10):2891–7.

Article  CAS  PubMed  Google Scholar 

Deshayes S, Coquerel A, Verdon R. Neurological adverse effects attributable to beta-lactam antibiotics: a literature review. Drug Saf. 2017;40(12):1171–98.

Article  CAS  PubMed  Google Scholar 

Sugimoto M, Uchida I, Mashimo T, et al. Evidence for the involvement of GABA(A) receptor blockade in convulsions induced by cephalosporins. Neuropharmacology. 2003;45(3):304–14.

Article  CAS  PubMed  Google Scholar 

Princeton NJ. Maxipime [package insert]: Bristol-Myers Squibb Company; 2023.

Wilmington DE. Merrem [package insert]: AstraZeneca Pharmaceuticals LP; 2023.

Madison NJ. Ceftazidime and avibactam [package insert]: AbbVie Inc; 2025.

Schmaldienst S, Traunmuller F, Burgmann H, et al. Multiple-dose pharmacokinetics of cefepime in long-term hemodialysis with high-flux membranes. Eur J Clin Pharmacol. 2000;56(1):61–4.

Article  CAS  PubMed  Google Scholar 

Meyer B, Guttmann C, Dittrich E, et al. Intermittent administration of beta-lactam antibiotics for treatment of severe infection in hemodialysis patients. Eur J Med Res. 2005;10(4):140–4.

CAS  PubMed  Google Scholar 

Descombes E, Martins F, Hemett OM, et al. Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study. BMC Pharmacol Toxicol. 2016;17:4.

Article  PubMed  PubMed Central  Google Scholar 

Ho V, Tay F, Wu JE, et al. The case for intermittent carbapenem dosing in stable haemodialysis patients. Antibiotics. 2020;9(11):815.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cimino C, Burnett Y, Vyas N, et al. Post-dialysis parenteral antimicrobial therapy in patients receiving intermittent high-flux hemodialysis. Drugs. 2021;81(5):555–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lewis SJ, Kays MB, Mueller BA. Use of Monte Carlo simulations to determine optimal carbapenem dosing in critically ill patients receiving prolonged intermittent renal replacement therapy. J Clin Pharmacol. 2016;56(10):1277–87.

Article  CAS  PubMed  Google Scholar 

Jang SM, Gharibian KN, Lewis SJ, et al. A monte carlo simulation approach for beta-lactam dosing in critically ill patients receiving prolonged intermittent renal replacement therapy. J Clin Pharmacol. 2018;58(10):1254–65.

Article  CAS  PubMed  Google Scholar 

Lewis SJ, Jang SM, Mueller BA. Vancomycin and daptomycin dosing recommendations in patients receiving home hemodialysis using Monte Carlo simulation. BMC Nephrol. 2023;24(1):270.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cronqvist J, Nilsson-Ehle I, Oqvist B, et al. Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment. Antimicrob Agents Chemother. 1992;36(12):2676–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Preston RA, Mamikonyan G, Mastim M, et al. Single-center investigation of the pharmacokinetics of WCK 4282 (cefepime-tazobactam combination) in renal impairment. Antimicrob Agents Chemother. 2019;63(10):e00873–19.

Article  PubMed  PubMed Central  Google Scholar 

Christensson BA, Nilsson-Ehle I, Hutchison M, et al. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 1992;36(7):1532–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rubino CM, Bhavnani SM, Loutit JS, et al. Single-dose pharmacokinetics and safety of meropenem-vaborbactam in subjects with chronic renal impairment. Antimicrob Agents Chemother. 2018;62(3):e02103-e2117.

Article  PubMed  PubMed Central  Google Scholar 

Goh JH, Lee SY, Ooi ST, et al. Post-hemodialysis dosing of 1 vs 2 g of ceftazidime in anuric end-stage renal disease patients on low-flux dialysis and its pharmacodynamic implications on clinical use. Hemodial Int. 2016;20(2):253–60.

Article  PubMed  Google Scholar 

Matzke GR, Frye RF, Joy MS, et al. Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Antimicrob Agents Chemother. 2000;44(6):1639–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Allaouchiche B, Breilh D, Jaumain H, et al. Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration. Antimicrob Agents Chemother. 1997;41(11):2424–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malone RS, Fish DN, Abraham E, et al. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother. 2001;45(11):3148–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tegeder I, Neumann F, Bremer F, et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther. 1999;65(1):50–7.

Article  CAS  PubMed  Google Scholar 

Krueger WA, Schroeder TH, Hutchison M, et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother. 1998;42(9):2421–4.

Article  CAS  PubMed  PubMed Central